I think many biotechnology companies prioritize rewards, especially when potential breakthroughs promise significant financial and clinical impact, but they cannot ignore risks due to regulatory scrutiny. Companies often balance risks and rewards by conducting formal risk-benefit analyses, which are required…   Read more»